Research In Motion Limited (USA) (NASDAQ: RIMM) shares took a hit, falling 15.33% to $7.74 per share for the pre-market trading session Friday after it was reported that the company delayed the make-or-break launch of its new BlackBerry phones until next year, in a devastating setback to the company whose sales are crumbling. RIMM closed Thursday with a slight deficit of 0.54% to $9.13 per share. Volume currently resides at 376,430.00, its average being 16.94M. RIMM’s MACD has taken a turn downwards, indicating decreased cash flow towards the company’s equity.
DO NOT BUY OR SELL RIMM UNTIL YOU READ THIS FREE TREND ANALYSIS REPORT: http://www.hotstockprofits.com/stockquotes/?q=RIMM
Smith & Wesson Holding Corporation (NASDAQ: SWHC) gained 16.84% to $8.05 early Friday during the pre-market trading session, after SWHC announced that for the first quarter of 2013, it expects net sales from continuing operations to be between $125.0 million and $130.0 million. For fiscal 2013, it expects net sales from continuing operations to be between $485.0 million and $505.0 million. SWHC closed the day Thursday on a sour note, falling 2.13% to $6.89 per share. SWHC has a reported RSI of 50.56, indicating an undersold level for the company.
DO NOT BUY OR SELL SWHC UNTIL YOU READ THIS FREE TREND ANALYSIS REPORT: http://www.hotstockprofits.com/stockquotes/?q=SWHC
Anthera Pharmaceuticals Inc. (NASDAQ: ANTH) plunged 5.77% to $0.760 per share for the pre-market trading session following news that its study for the treatment of lupus failed to meet its primary target. The firm’s phase 2b Pearl-SC study was aiming to identify an effective and safe dose of its treatment blisibimod for future phase three clinical studies to differentiate it from existing lupus therapies. ANTH shares plummeted Thursday, closing with a deficit of 70.67% to $0.807 per share. Volume rose to 4,555.00 shares before the morning bell, alongside a market capitalization of 33.13M.
DO NOT BUY OR SELL ANTH UNTIL YOU READ THIS FREE TREND ANALYSIS REPORT: http://www.hotstockprofits.com/stockquotes/?q=ANTH
Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX) jumped 4.35% for Friday’s pre-market trading session, rising to $2.40 per share after the company reported the publication of results from two initial trials of LX4211 in patients with type 2 diabetes in the online edition of the journal Clinical Pharmacology & Therapeutics. LXRX closed Thursday with an increase of 0.44% to $2.30 per share. Volume rose to 13,316.00 shares, alongside a market capitalization of 1.11B.
DO NOT BUY OR SELL LXRX UNTIL YOU READ THIS FREE TREND ANALYSIS REPORT: http://www.hotstockprofits.com/stockquotes/?q=LXRX
HotStockProfits.com is owned and operated by ALG Financial, a full-service financial communications and investor relations firm. HotStockProfits.com continuously monitors and scans the markets for day trading and swing trading signals on NASDAQ, NYSE, AMEX, OTCBB and Pink Sheet companies for its free e-newsletter subscribers.
Subscribe to the FREE e-newsletter: www.HotStockProfits.com
Disclosure: HotStockProfits.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please visit HotStockProfits.com website, for complete risks and disclosures.